Sucampo Pharmaceuticals, Inc.
DelistedCIK 1365216fmd_0YZ7WF54N81ZAKN4N7K7SSRJPQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2017, 31 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 67 | 62 | 55 | 81 | 90 | 115 | 153 | 230 |
| Cost of revenue | – | – | – | 3 | 12 | 16 | 37 | 76 |
| Realized investment gains (losses) | (2) | (1) | – | – | – | – | – | – |
| Gross profit | – | 62 | 55 | 78 | 77 | 99 | 116 | 154 |
| Research and development | 33 | 24 | 33 | 21 | 22 | 21 | 34 | 47 |
| Selling, general and administrative | 25 | 38 | 50 | 49 | 46 | 46 | 38 | 46 |
| Operating income | 9 | (0) | (18) | 8 | 9 | 27 | 44 | 54 |
| Interest expense | – | 0 | 2 | 2 | 2 | 2 | 7 | 24 |
| Interest and investment income | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | (3) | (4) | (0) | 2 | (0) | (1) | (40) |
| Income before taxes | 10 | (3) | (22) | 8 | 11 | 27 | 44 | 14 |
| Income tax expense | 5 | (1) | (5) | 3 | 4 | 14 | 10 | (4) |
| Net income from continuing operations | 5 | (3) | (17) | 5 | 7 | 13 | 33 | 18 |
| Net income | 5 | (3) | (17) | 5 | 7 | 13 | 33 | 18 |